Manos Papadakis

This inventor holds 11 USPTO granted patents and 21 published patent applications and 1 EPO patent. Top assignees: Glycom A/s, Dsm IP Assets B.v.. Active years: 2020-2026.

USPTO Granted Patents = 11 (Patent Applications = 21)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 31)

Average Co-Inventor Count = 1.6

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

København, DK (2020)
Copenhagen, DK (2022 - 2024)

Company Filing History:

Years Active: 2020-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662691 - HMO PRODUCTION (2026-06-23),

2. 12553071 - GENETICALLY ENGINEERED STRAINS WITH REDUCED BYPRODUCT FORMATION (2026-02-17),

3. 12534701 - MICROBIAL STRAIN EXPRESSING AN INVERTASE/SUCROSE HYDROLASE (2026-01-27),

4. 12416030 - Identification of an α-1,2-fucosyltransferase for the in vivo production of pure LNFP-I (2025-09-16),

5. 12351806 - HMO production (2025-07-08),

6. 12286658 - Enhancing formation of milk oligosaccharides (HMOs) by modifying lactose import in the cell (2025-04-29),

7. 12188056 - Sialyltransferases for in vivo synthesis of 3'SL (2025-01-07),

8. 11926858 - Oligosaccharide production (2024-03-12),

9. 11608504 - Nucleic acid construct for in vitro and in vivo gene expression (2023-03-21),

10. 11293042 - Oligosaccharide production (2022-04-05),

11. 10829508 - Fermentative production of oligosaccharides (2020-11-10),

Title: Manos Papadakis: Innovator in Human Milk Oligosaccharides

Introduction

Manos Papadakis is a notable inventor based in Hørsholm, Denmark. He has made significant contributions to the field of biotechnology, particularly in the production of human milk oligosaccharides (HMOs). With a total of 11 patents, his work focuses on enhancing the production and transport of these vital compounds.

Latest Patents

One of his latest patents is titled "Identification of an α-1,2-fucosyltransferase for the in vivo production of pure LNFP-I." This patent discloses the identification and introduction of a specific heterologous gene, known as smob, which encodes an α-1,2-fucosyltransferase. This gene originates from a sulfur-oxidizing bacterium isolated from brackish lake sediment. The introduction of this gene into an LNT production strain allows for the production of LNFP-I.

Another significant patent by Papadakis is "Enhancing formation of milk oligosaccharides (HMOs) by modifying lactose import in the cell." This invention relates to a method of producing one or more HMOs, particularly LNT and/or LNnT, in a genetically engineered cell. The genetically modified cell is designed to enhance oligosaccharide transport capability, enabling the production of HMOs and improving lactose transport.

Career Highlights

Manos Papadakis is currently associated with Dsm IP Assets B.V., where he continues to innovate in the field of biotechnology. His work has been instrumental in advancing the understanding and production of HMOs, which are crucial for infant nutrition and health.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Manos Papadakis is a pioneering inventor whose work in the field of human milk oligosaccharides has the potential to impact infant nutrition significantly. His innovative patents reflect his commitment to advancing biotechnology and improving health outcomes.